Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 111

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 111
---
 price of $9.80 per         
 share, which warrants were sold to certain investors pursuant to the Third Securities Purchase Agreement (the “Series C Warrants”);      
 and (ii) 558,617 shares of Common Stock issuable upon the conversion of shares of Series A Preferred Stock resulting from the exercise   
 of outstanding Series A Preferred Warrants.                                                                                              |

<div align='center'>56</div>

In addition to any resales
pursuant to such registration statements, subject to applicable transfer restrictions and the conditions to the availability of Rule
144 for former shell companies under Rule 144(i), shares of Common Stock held by these stockholders will be eligible for resale, potentially
subject to, in the case of stockholders who are our affiliates, volume, manner of sale, and other limitations under Rule 144 promulgated
under the Securities Act.

In addition, shares of our
Common Stock issuable upon exercise or vesting of incentive awards under our incentive plans are, once issued, eligible for sale in the
public market, subject to any lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates
under Rule 144. Furthermore, shares of our Common Stock reserved for future issuance under our incentive plan may become available for
sale in future.

The market price of shares
of our Common Stock could drop significantly if the holders of the shares of Common Stock described above sell them or are perceived
by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future
offerings of shares of our Common Stock or other securities.

Certain existing securityholders purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in us may not experience a similar rate of return.

Certain of our securityholders
acquired our securities at prices below the current trading prices of our Common Stock and Public Warrants and may experience a positive
rate of return based on the current trading prices. In particular, the effective purchase prices at which certain Legacy CERo Stockholders
and the Sponsor acquired their shares of our Common Stock are generally substantially less than the Initial Public Offering price of
$1,000.00 per share, after giving effect to the Exchange Ratio (as defined in the Business Combination Agreement). Consequently, these
securityholders may have an incentive to sell their shares of our Common Stock even if the trading price is below the price